Dr Paul Morrison

Key Appointments

• Consultant Psychiatrist & Clinical Lead, Argyll & Bute, NHS Highland

• Honorary Clinical Senior Lecturer, King’s College London

• Former Research Psychiatrist at the Institute of Psychiatry & National Psychosis Unit at Bethlem Hospital

Years of Experience

20+ years in psychiatry and CNS clinical research, including large, complex and controlled-drug studies.

Therapeutic Areas (CNS & Psychiatry)

PTSD, Treatment-Resistant Depression, Major Depressive Disorder, Alcohol Use Disorder, Schizophrenia, Psychosis Risk, Paranoia, Anxiety Disorders, Cognitive Disorders.

Drug Classes & Modalities

DMT (buccal film), 5-MeO-DMT, methylone, psilocybin, MDMA, cannabidiol (CBD), THC, THCV, inhaled CNS compounds, sodium nitroprusside, oxytocin, and experimental psychopharmacology agents using EEG, SPET, VR and neurocognitive endpoints.

Clinical Trials Experience

• PI or Co-Investigator on numerous Phase I–II CNS and psychedelic studies, including: Multiple PTSD trials using methylone (Phase II), DMT and 5-MeO-DMT studies in TRD and AUD (Phase II), and CBD trials in schizophrenia, psychosis and cannabis dependence

• Designed numerous trials with >200 participants

• Extensive experience across masked, randomised, placebo-controlled, crossover, and open-label extension trial designs

• Early experimental work demonstrating CBD’s inhibition of THC-induced psychosis and memory impairment